The University of Texas MD Anderson Cancer Center is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the U.S. and one of the original three comprehensive cancer centers in the country.

During the past decade, University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner" are "Advanced Solid Tumor" (1 trials), "Breast Cancer" (1 trials), "Metastatic or Locally Advanced Unresectable Solid Tumors" (1 trials) and "Solid Tumors" (1 trials). Many other conditions were trialed in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner" in a lesser frequency.

Most popular intervention types in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (2 trials), "Capecitabine" (1 trials), "Carboplatin" (1 trials), "Cisplatin" (1 trials) and "Eribulin" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner" are 4 trials for "All" genders.

Currently, there are NaN active trials in "University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner, 3 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".